Immix Biopharma | Investor Presentation Deck | 61 slides · page 58 of 61
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.
Pitch deck · comparison_table · compare_peers · balanced density
Slide locked Sign in to view
Slide schematic 3/3
source-note 1/1 table 1/1 title 1/1
Components 3
source-note data headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1